Adaptive Biotechnologies Corporation

NasdaqGS:ADPT Aktierapport

Börsvärde: US$2.2b

Adaptive Biotechnologies Förvaltning

Förvaltning kriterier kontrolleras 2/4

Adaptive Biotechnologies VD är Chad Robins, utsedd i Sep 2009, har en mandatperiod på 16.67 år. totala årliga ersättningen är $ 9.08M, bestående av 7.7% lön 92.3% bonusar, inklusive företagsaktier och optioner. äger direkt 0.99% av företagets aktier, värda $ 21.44M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 7.6 år respektive 12.4 år.

Viktig information

Chad Robins

Verkställande direktör

US$9.1m

Total ersättning

VD-lön i procent7.69%
Anställning som VD16.7yrs
Ägande av VD1.0%
Ledningens genomsnittliga anställningstid7.6yrs
Styrelsens genomsnittliga mandatperiod12.4yrs

Senaste uppdateringar av ledningen

Recent updates

ADPT: 2026 MRD Outlook And Margin Discipline Will Drive Future Upside Potential

The updated analyst price target for Adaptive Biotechnologies moves slightly lower to about $20.57 from $20.86. Analysts attribute this change to modest adjustments to fair value estimates, discount rate assumptions, and longer term profit margin and P/E expectations.

ADPT: MRD Revenue Outlook And Refreshed Models Will Support Future Cash Flows

Narrative Update on Adaptive Biotechnologies The consensus analyst price target for Adaptive Biotechnologies has moved up by $1, reflecting updated analyst models that incorporate adjusted discount rates, refreshed revenue growth and profit margin assumptions, and a revised, still very large forward P/E framework. Analyst Commentary Recent Street research on Adaptive Biotechnologies centers on modestly higher price targets, with several bullish analysts revising their models at roughly the same time.

ADPT: MRD 2026 Outlook And Discount Assumptions Will Support Future Upside Potential

Analysts have raised their price targets on Adaptive Biotechnologies by about $1, reflecting updated views on discount rates, growth, margins, and future P/E assumptions. These changes keep the stock's fair value estimate effectively unchanged at around $21.

ADPT: MRD Outlook And Pfizer Agreements Will Support Future Cash Flows

Analysts have inched their average price targets on Adaptive Biotechnologies higher, often by about $1 increments. These changes reflect updated views that modestly adjust revenue growth, profit margin and future P/E assumptions while keeping the fair value estimate near $22.

ADPT: MRD And Pfizer Agreements Will Support Future Cash Flow Upside

The analyst price target for Adaptive Biotechnologies has shifted from $21.00 to $22.00. Analysts point to updated assumptions around growth, profitability, and long-term P/E expectations following a series of recent target increases across the Street.

ADPT: Pfizer Agreements And MRD Progress Will Support Future Upside Potential

Analysts have nudged their average price target for Adaptive Biotechnologies higher by about $1, reflecting updated fair value assumptions and slightly revised views on growth, margins and future P/E, in line with recent target increases from several research firms. Analyst Commentary Recent research updates cluster around modest target increases and a generally supportive view of Adaptive Biotechnologies, with most of the focus on refreshed fair value work rather than sweeping changes to the thesis.

ADPT: Sector Tailwinds And Pfizer Partnerships Will Support Measured Future Upside

Analysts have nudged their price targets on Adaptive Biotechnologies slightly higher, with Street research pointing to target increases such as TD Cowen moving to $20 from $19. This contributes to a modest lift in our fair value estimate from $20.00 to about $20.14 as they highlight solid expected sector results and fundamentals.

ADPT: Sector Tailwinds And Cancer Testing Leadership Will Support Future Upside

Narrative Update: Adaptive Biotechnologies The analyst price target for Adaptive Biotechnologies has moved from $19 to $20, reflecting updated views that incorporate recent Q4 preview work on diagnostics peers, expectations for solid sector results and 2026 outlooks, and the company’s latest Q3 report. Analyst Commentary Recent Street research around Adaptive Biotechnologies has focused on updated price targets that reflect fresh sector work and the company’s latest Q3 report.

ADPT: MRD Platform And Pfizer Agreements Will Support Long-Term Cash Flow Upside

Analysts have lifted their price target on Adaptive Biotechnologies to $16 from $11, citing the recent Q3 report as the key driver behind this updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the new US$16 price target, up from US$11, as a sign that expectations for execution and risk reward have shifted in a more constructive direction after the recent Q3 report.

Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle

Dec 26

ADPT: MRD Leadership Will Drive Long-Term Cash Flow Upside

Analysts have raised their fair value estimate for Adaptive Biotechnologies from approximately $15 to $21 per share. They cite higher long term profit margin expectations and confidence in the company’s leadership in minimal residual disease cancer testing, even with moderating revenue growth assumptions and a higher discount rate.

ADPT: Future Revenue Will Be Sustained By Leadership In Cancer Testing

Analysts have raised their fair value estimate for Adaptive Biotechnologies to $19.57 from $19.14. They cite increased confidence in the company's sustained revenue growth and leadership position in cancer testing.

ADPT: Future Revenue Will Be Driven By Market Expansion In Blood Cancer Testing

Analysts have raised their price target for Adaptive Biotechnologies by $2.00 to $19.14, citing the company's leadership in minimal residual disease testing, as well as expectations for sustained revenue growth and improved margins. Analyst Commentary Recent analyst discussions reveal diverse perspectives on Adaptive Biotechnologies' position in the market and future prospects.

ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks

Analysts have increased their price target for Adaptive Biotechnologies from $16.00 to $17.14 per share. They cite continuing leadership in cancer testing and expectations for robust revenue growth, driven by market expansion and operational improvements.

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors

Oct 16
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Analysts have increased their price target for Adaptive Biotechnologies from $14 to approximately $14.86 per share. They cite ongoing revenue growth momentum and strengthening leadership in the cancer diagnostics market as key drivers of the upward revision.

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

Sep 24
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 28% Share Price Bounce

Aug 29
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 28% Share Price Bounce

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Despite a modest decline in consensus revenue growth forecasts and a slight increase in the discount rate, the consensus analyst price target for Adaptive Biotechnologies has been raised from $11.86 to $13.29. What's in the News Raised full year 2025 MRD business revenue guidance to $190–200 million from the prior $180–190 million range; no revenue guidance for Immune Medicine.

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 29% Higher

May 31
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 29% Higher

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?

May 07
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?

Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge

Apr 10
Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge
User avatar

ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines

Strategic partnerships and initiatives to raise test prices and efficiency are expected to drive substantial revenue and margin growth.

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher

Feb 14
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher

Adaptive Biotechnologies: Making Some Progress

Nov 26

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Nov 26
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Analys av ersättningar till VD

Hur har Chad Robins:s ersättning förändrats jämfört med Adaptive Biotechnologies:s resultat?
DatumTotal ersättningLönFöretagets resultat
Dec 31 2025US$9mUS$698k

-US$59m

Sep 30 2025n/an/a

-US$80m

Jun 30 2025n/an/a

-US$121m

Mar 31 2025n/an/a

-US$142m

Dec 31 2024US$5mUS$678k

-US$159m

Sep 30 2024n/an/a

-US$195m

Jun 30 2024n/an/a

-US$213m

Mar 31 2024n/an/a

-US$215m

Dec 31 2023US$9mUS$663k

-US$225m

Sep 30 2023n/an/a

-US$196m

Jun 30 2023n/an/a

-US$191m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$9mUS$658k

-US$200m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$229m

Dec 31 2021US$9mUS$639k

-US$207m

Sep 30 2021n/an/a

-US$190m

Jun 30 2021n/an/a

-US$171m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$597k

-US$146m

Sep 30 2020n/an/a

-US$122m

Jun 30 2020n/an/a

-US$99m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$3mUS$493k

-US$70m

Ersättning vs marknad: Chad s total kompensation ($USD 9.08M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 5.47M ).

Ersättning vs inkomst: Ersättningen för Chad har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

Chad Robins (50 yo)

16.7yrs
Anställning
US$9,081,690
Kompensation

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Chad Robins
Co-Founder16.7yrsUS$9.08m0.99%
$ 21.4m
Julie Rubinstein
President & COO8.3yrsUS$4.60m0.25%
$ 5.4m
Harlan Robins
Co-Founder & Chief Scientific Officer16.7yrsUS$8.51m0.98%
$ 21.3m
Kyle Piskel
VP, CFO & Principal Accounting Officer4.6yrsUS$3.31m0.031%
$ 676.3k
Susan Bobulsky
Chief Commercial Officer of MRD5.8yrsUS$3.55m0.087%
$ 1.9m
Christopher Carlson
Founderno datainga uppgifteringa uppgifter
Karina Calzadilla
Vice President of Investor Relationsno datainga uppgifteringa uppgifter
Clarice McCauley
Head of Legalno datainga uppgifteringa uppgifter
Francis Lo
Chief People Officer7yrsinga uppgifter0.18%
$ 3.9m
Sharon Benzeno
Chief Commercial Officer of Immune Medicine8.3yrsUS$1.80m0.18%
$ 3.8m
Mary Lancelotta
Senior Vice President of MRD BioPharma2.7yrsinga uppgifteringa uppgifter
7.6yrs
Genomsnittlig anställningstid
50yo
Genomsnittlig ålder

Erfaren ledning: ADPT s ledningsgrupp är erfaren och erfaren ( 7.6 års genomsnittlig anställning).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Chad Robins
Co-Founder16.7yrsUS$9.08m0.99%
$ 21.4m
Peter Neupert
Lead Independent Director12.4yrsUS$355.00k0.15%
$ 3.2m
H. Parker
Member of Corporate Advisory Boardno datainga uppgifteringa uppgifter
Michelle Griffin
Independent Director7.2yrsUS$330.00k0%
$ 0
Robert Hershberg
Independent Director13.3yrsUS$325.00k0.030%
$ 658.7k
Carol Gallagher
Member of Corporate Advisory Boardno datainga uppgifteringa uppgifter
Craig Weissman
Member of Corporate Advisory Boardno datainga uppgifteringa uppgifter
Graham Allen
Member of Corporate Advisory Boardno datainga uppgifteringa uppgifter
Matthew Kahn
Member of Corporate Advisory Boardno datainga uppgifteringa uppgifter
Katey Owen
Independent Director5.2yrsUS$310.00k0.047%
$ 1.0m
12.4yrs
Genomsnittlig anställningstid
60yo
Genomsnittlig ålder

Erfaren styrelse: ADPT s styrelse är rutinerade och erfaren ( 12.4 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/01 14:30
Aktiekurs vid dagens slut2026/05/01 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Adaptive Biotechnologies Corporation bevakas av 13 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Derik de BruinBofA Global Research
Mark MassaroBTIG
William BonelloCraig-Hallum Capital Group LLC